Co-Diagnostics, Inc. - Common Stock (CODX)
Investment Snapshot
- P/B of 0.46 — trading below book value
- Piotroski F-Score 1/9 — signs of financial weakness
- Loss-making — negative ROE of -149.5%
- Revenue declining 84% annually
Co-Diagnostics, Inc. - Common Stock (CODX) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $9 million . Key value metrics: P/B ratio 0.46, Piotroski F-Score 1 out of 9 .
Value Score
Key Metrics
Co-Diagnostics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, CODX shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and negative return on equity of -149.5%.
StockPik's composite Value Score for CODX is 57/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CODX reports a high gross margin of 62.3% and a negative operating margin of -3,386.8%.
CODX shows revenue declining at 84% year-over-year, with earnings declining at 25%.